Madrigal Pharmaceuticals Financials - Benzinga

Madrigal Pharmaceuticals Inc

MDGLNASDAQ

Trade with Public

Trade with Public

$516.56

3.350.65%

가까이에: Sep 25, 5:00 PM EST

$516.56

N/A

시간외: 4:40 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Madrigal Pharmaceuticals Financials

Madrigal Pharmaceuticals (MDGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per

Benzinga Newsdesk

PRO
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate

Benzinga Newsdesk

Earnings Scheduled For February 19, 2026

Benzinga Insights

Earnings Preview For Madrigal Pharmaceuticals

Benzinga Insights

© 2026 Benzinga | All Rights Reserved